Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Earnings Call Recording

 Pursuant to Regulation 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform the exchanges that the recording of the Earnings Call held on Tuesday, 24 January 2023 at 05:00 p.m. IST is available on the website of the Company. The recording can be accessed from the following link: https://www.tatvachintan.com/wp-content/uploads/2023/01/ICI3420230124144995.mp3 The above information is available on the website of the Company at www.tatvachintan.com.
24-01-2023

Tatva Chintan Pharma Chem Results Earnings Call for Q3FY23

 Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
24-01-2023
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and nine months ended 31 December 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com.
24-01-2023
Bigul

Q3FY23 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.

 Specialty chemicals firm Tatva Chintan Pharma Chem announced Q3FY23 results: Consolidated Q3FY23 vs Q3FY22: Revenue from Operations for the quarter was Rs 1,206 million, increased by 15% EBITDA for the quarter was Rs 179 million, declined by 25% EBIDTA Margin for the quarter was at 15% Net Profit for the quarter was Rs 116 million, declined by 49% Net Profit Margin for the quarter was at 10% Basic and Diluted EPS for the quarter was Rs 5.24 per share 9MFY23 vs 9MFY22: Revenue from Operations for the nine months was Rs 2,991 million, declined by 11% EBITDA for the nine months was Rs 443 million, declined by 49% EBIDTA Margin for the nine months was at 15% Net Profit for the nine months was Rs 285 million, declined by 64% Net Profit Margin for the nine months was at 10% Basic and Diluted EPS for the nine months was Rs 12.87 per share Commenting on the results, Mr. Chintan Shah, Managing Director said during this quarter, the company reported revenue of Rs 1,206 million, a growth of 15% YoY and 34% QoQ respectively. As anticipated, improved offtake in SDA segment is reflected in numbers of this quarter. EBITDA during this quarter was Rs 179 million, a decline of 25% YoY and a growth of 60% QoQ respectively. Net Profit was Rs 116 million, a decline of 49% YoY and a growth of 63% QoQ basis. During the quarter, prices of basic chemicals and commodities continue to remain very high. We have witnessed rampant currency fluctuations across various geographies this quarter, particularly adverse movements in Euro and Yen. Keeping in mind our long-term partnerships and associations with select key customers belonging to these geographies, we marginally reduced the prices and, in few cases, opted not to ask for price increase and absorbed certain increased costs ourselves. During the quarter, the inventory at consolidated levels have come down from Rs 2,030 to Rs 1,762 million. During this quarter, there is a marginal decline in power/fuel costs, and significant drop in shipping cost since mid-November. The solvent prices have started to rationalize since Q3FY23. By demonstrating our capabilities to run specialized chemistries, we are seeing a consistent rise in the confidence and comfort of large customers. There have been developments in R&D;, plant scale trials in various product categories during the quarter. The key watch areas would remain how the European energy crisis roll out over the next few months and how the demand revival for heavy duty commercial vehicles pans out. Also, with the China economy opening up, it would be important to observe how quickly their business rebounds. We are happy to inform that the capex at our Dahej SEZ plant is completed and trial runs are underway. Please note that nearly 93% of the IPO funds have been utilized so far. The expansion of R&D; facility at Vadodara is on finishing stage. Result PDF
24-01-2023
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and nine months ended 31 December 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com.
24-01-2023
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2022

 Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.
24-01-2023
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 24.01.2023

 Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.
24-01-2023
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and nine months ended 31 December 2022, is scheduled on Tuesday, 24 January 2023 at 05:00 p.m. IST. The Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records. The above information shall be made available on the website of the Company at www.tatvachintan.com.
13-01-2023
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Intimation for Consider, Approve And Take On Record The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended 31 December 2022.

 Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 ,inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 January 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information shall be made available on the website of the Company at www.tatvachintan.com.
13-01-2023
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed Compliance Certificate for the quarter ended 31 December 2022, received from M/s Link Intime India Private Limited, our Registrar and Share Transfer Agent. The above information shall be uploaded on the website of the Company at www.tatvachintan.com.
07-01-2023
Next Page
Close

Let's Open Free Demat Account